Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 14/20 | 0.40 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.40 |
| ▸ | TOP1 | P11387 | 6/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19728767 | 0.91 | CYP3A4 (0.52) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL19728599 | 0.91 | TOP2A (0.42) | CYP3A4CYP2C9TOP2ATOP2BTOP1 | |
| SCHEMBL19729114 | 0.90 | CYP3A4 (0.51) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL19729363 | 0.89 | CYP3A4 (0.49) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL19728764 | 0.88 | CYP3A4 (0.64) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL19729374 | 0.88 | CYP3A4 (0.55) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL19729356 | 0.87 | CYP3A4 (0.37) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL19728747 | 0.86 | CYP3A4 (0.48) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL19729305 | 0.85 | CYP3A4 (0.51) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 | |
| SCHEMBL19728771 | 0.84 | CYP3A4 (0.44) | CYP3A4CYP2C9ALDH1A1POLBCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2019-09-12 | — | — | US | disclosed |
| EP-3473616-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | Wakunaga Pharmaceutical Co., Ltd. (JP) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017217441-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | 湧永製薬株式会社 | 2017-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276407-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVE OR SALT THEREOF | CTR9, PYCR1, ACAD9 | CYP3A4 3514/4885CYP2C9 154/4885ALDH1A1 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.